Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0843007/Idiopathic-Thrombocytopenic-Purpura-ITP-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Introduction 72.1 Overview 72.2 Classification of Idiopathic Thrombocytopenic Purpura 72.3 Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura 82.4 Epidemiology 92.5 Clinical Symptoms 92.6 Diagnosis and Management of Idiopathic Thrombocytopenic Purpura 92.7 Treatment of Idiopathic Thrombocytopenic Purpura 112.8 GlobalData Pipeline Report Guidance 123 Idiopathic Thrombocytopenic Purpura Therapeutics - Market Characterization 133.1 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Global 133.2 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Global 143.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the US 153.4 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the US 163.5 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the UK 173.6 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the UK 183.7 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - France 193.8 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - France 203.9 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Germany 213.10 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Germany 223.11 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Italy 233.12 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Italy 243.13 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Spain 253.14 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Spain 263.15 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Japan 273.16 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Japan 283.16.1 Drivers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 293.16.2 Barriers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 293.17 Key Events Impacting the Future Market 303.18 Opportunity and Unmet Need 313.19 Key Takeaway 324 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Competitive Assessment 334.1 Overview 334.2 Strategic Competitor Assessment 334.3 Product Profiles for the Major Marketed Products in the Idiopathic Thrombocytopenic Purpura Therapeutics Market 344.3.1 Nplate (romiplostim) 344.3.2 Promacta/Revolade (eltrombopag) 344.4 Key Takeaway 355 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Pipeline Assessment 365.1 Overview 365.1.1 Strategic Pipeline Assessment 365.2 Idiopathic Thrombocytopenic Purpura Therapeutics Pipeline Analysis - Pipeline by Clinical Phases of Development 365.2.1 ITP Therapeutics - Phase III Clinical Pipeline 365.2.2 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Clinical Pipeline 375.2.3 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Clinical Pipeline 375.2.4 Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline 375.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Clinical Pipeline by Mechanism of Action 385.4 Idiopathic Thrombocytopenic Purpura Technology Trends Analytical Framework 395.5 Molecule Profile for Late-Stage Drugs under Clinical Development 405.5.1 IGIV3I 10% Grifols 405.5.2 Mabthera (rituximab) 415.6 Key Takeaway 416 Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials Mapping 426.1 Clinical Trials by Country 426.2 Clinical Trials by Phase 436.3 Clinical Trials by Trial Status 446.4 Overall Sponsors 456.5 Prominent Sponsors 466.6 Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials 477 Idiopathic Thrombocytopenic Purpura Therapeutics - Strategic Assessment 487.1 Future Market Competition Scenario 488 Idiopathic Thrombocytopenic Purpura Therapeutics - Future Players 498.1 Introduction 498.2 Company Profiles 508.2.1 F. Hoffmann-La Roche 508.2.2 Grifols Biologicals Inc. 518.2.3 Amgen Inc. 518.2.4 GlaxoSmithKline plc 538.2.5 Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 559 Idiopathic Thrombocytopenic Purpura Therapeutics - Licensing and Partnership Deals 5610 Idiopathic Thrombocytopenic Purpura Therapeutics - Appendix 5710.1 Definitions 5710.2 Acronyms 5710.3 Research Methodology 5810.3.1 Coverage 5810.3.2 Secondary Research 5810.3.3 Forecasting 5910.3.4 Primary Research 6110.3.5 Expert Panel Validation 6210.4 Contact Us 6210.5 Disclaimer 6210.6 Bibliography 62
List of Tables
Table 1: Classification of Idiopathic Thrombocytopenic Purpura 7Table 2: Prevalence of Idiopathic Thrombocytopenic Purpura, 2011 9Table 3: Diagnostic Tools for Idiopathic Thrombocytopenic Purpura 10Table 4: Treatment of Idiopathic Thrombocytopenic Purpura according to Haematological Societies Guidelines 11Table 5: Characteristics of Existing Major Drugs for Idiopathic Thrombocytopenic Purpura 11Table 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006 - 2011 13Table 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Forecast ($m), 2011 - 2019 14Table 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011 15Table 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2011 - 2019 16Table 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 17Table 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 18Table 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011 19Table 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019 20Table 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 21Table 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 22Table 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 23Table 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 24Table 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 25Table 19: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 26Table 20: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 27Table 21: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 28Table 22: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase III Pipeline 36Table 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Pipeline 37Table 24: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Pipeline 37Table 25: Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline 37Table 26: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011 42Table 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011 43Table 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011 44Table 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011 45Table 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Prominent Sponsors, 2011 46Table 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Top Companies Participating in Clinical Trials, 2011 47Table 32: F. Hoffmann-La Roche - Idiopathic Thrombocytopenic Purpura Pipeline, 2011 50Table 33: Grifols Biologicals Inc.- Idiopathic Thrombocytopenic Purpura Pipeline, 2011 51Table 34: Amgen Inc. - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 52Table 35: GlaxoSmithKline plc - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 54Table 36: Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 55Table 37: Idiopathic Thrombocytopenic Purpura Therapeutics: Licensing and Partnership Deals 56
List of Figures
Figure 1: Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura 8Figure 2: Management Algorithm for Idiopathic Thrombocytopenic Purpura 10Figure 3: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006-2011 13Figure 4: ITP Therapeutics Market, Global, Forecast ($m), 2011 - 2019 14Figure 5: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011 15Figure 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Forecast ($m), 2011 - 2019 16Figure 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 17Figure 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 18Figure 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011 19Figure 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019 20Figure 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 21Figure 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 22Figure 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 23Figure 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 24Figure 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 25Figure 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 26Figure 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 27Figure 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 28Figure 19: Idiopathic Thrombocytopenic Purpura Therapeutics, Key Events Impacting Future Market 30Figure 20: Opportunity and Unmet Need in the First-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 31Figure 21:Opportunity and Unmet Need in the Second-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 32Figure 22: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Strategic Competitor Assessment, 2011 33Figure 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Pipeline by Phase of Clinical Development, 2011 36Figure 24: Idiopathic Thrombocytopenic Purpura Therapeutics, Clinical Pipeline by Mechanism of Action, 2011 38Figure 25: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, 2011 39Figure 26: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, Description, 2011 40Figure 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011 42Figure 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011 43Figure 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011 44Figure 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011 45Figure 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical trials by Prominent Sponsors, 2011 46Figure 32: Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials, 2011 47Figure 33: Idiopathic Thrombocytopenic Purpura Therapeutics, Strategic Assessment, 2011 48Figure 34: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Future Players, 2011 49Figure 35: GlobalData Market Forecasting Model 61
Companies mentioned
F. Hoffmann-La Roche
Grifols Biologicals Inc.
Amgen Inc.
GlaxoSmithKline plc
To order this report:: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article